StreetInsider.com News Articles

Form 4 IMPACT BIOMEDICAL INC. For: Sep 22 Filed by: DSS, INC.

Thu, 24 Sep 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260924/27103182.html

Form 8-K IMPACT BIOMEDICAL INC. For: Sep 16

Thu, 17 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260917/27072177.html

Zoar files Form F-4 for Impact Biomedical business combination

Wed, 16 Sep 2026 09:26:26 -0400

DSS, Inc. (NYSE American: DSS) announced that Zoar Limited has filed a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission in connection with a proposed business combination involving Impact Biomedical Inc. (NYSE American: IBO).

The Registration Statement includes a preliminary proxy statement from Impact Biomedical and a prospectus from Zoar relating to the proposed transaction. The filing remains subject to SEC review and has not been declared effective.

DSS, which holds a significant ownership stake in Impact Biomedical, said the filing marks a step toward completing the transaction. Jason Grady, Chief Executive Officer of DSS, said: "The filing

Zoar files Form F-4 for Impact Biomedical business combination

Wed, 16 Sep 2026 09:26:26 -0400

DSS, which holds a significant ownership stake in Impact Biomedical, said the filing marks a step toward completing the transaction. Jason Grady, Chief Executive Officer of DSS, said: "The filing

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

Wed, 16 Sep 2026 09:25:00 -0400

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

Wed, 16 Sep 2026 09:25:00 -0400

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

Wed, 16 Sep 2026 09:25:00 -0400

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

Wed, 16 Sep 2026 09:25:00 -0400

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to

Impact Biomedical files Form F-4 for merger with Zoar Ltd.

Wed, 16 Sep 2026 09:20:54 -0400

Impact Biomedical Inc. (NYSE: IBO) announced that Zoar Limited filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission on Sept. 10, 2026, in connection with a proposed business combination between Impact Biomedical and Zoar Ltd., formerly known as Dr. Ashley's Limited.
The registration statement includes Impact's preliminary proxy statement and is available on the SEC's website under the name "Zoar Limited." A definitive proxy statement will be mailed to Impact stockholders once the registration statement is declared effective by the SEC.
Completion of the business combination is subject to several conditions, including the SEC declaring the registration statement

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

Wed, 16 Sep 2026 09:20:00 -0400

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Zoar Labs”), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

Wed, 16 Sep 2026 09:20:00 -0400

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Zoar Labs”), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at

Form 8-K IMPACT BIOMEDICAL INC. For: Sep 14

Tue, 15 Sep 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260915/27060596.html

Impact Biomedical sets 1-for-12.62 reverse split ahead of merger

Mon, 14 Sep 2026 21:27:04 -0400

Impact Biomedical Inc. (NYSE American: IBO) has corrected a previously issued press release to fix an error in the merger exchange ratio related to its proposed combination with Zoar Limited, formerly known as Dr Ashleys Limited.

The original Sept. 11, 2026 release incorrectly stated that Impact stockholders would receive one share of Zoar Limited for every four shares of Impact common stock. The correct ratio, as set forth in the Merger and Share Exchange Agreement filed with the Securities and Exchange Commission on June 23, 2025, is one share of Zoar Limited for every one share of Impact common stock held

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

Mon, 14 Sep 2026 21:26:00 -0400

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

Mon, 14 Sep 2026 21:26:00 -0400

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession

Impact BioMedical announces 1-for-12.62 reverse stock split ahead of merger

Fri, 11 Sep 2026 16:05:20 -0400

Impact BioMedical Inc. (NYSE American: IBO) announced that its board of directors has approved a 1-for-12.62 reverse stock split of its issued and outstanding common stock, effective at 12:01 a.m. Eastern Time on September 23, 2026.

The company's common stock will continue to trade on the NYSE American exchange under the ticker symbol IBO but will carry a new CUSIP number following the split. The reverse stock split will reduce shares outstanding from approximately 107,821,231 to 8,543,679, subject to minor rounding adjustments.

Stockholders approved a second reverse stock split on December 30, 2025, authorizing a ratio of between 1-for-12.48 and 1-for-50, to

Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)

Fri, 11 Sep 2026 16:05:00 -0400

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in

Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)

Fri, 11 Sep 2026 16:05:00 -0400

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in

Form 10-Q IMPACT BIOMEDICAL INC. For: Jun 30

Fri, 07 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260807/26891585.html

Form 10-Q IMPACT BIOMEDICAL INC. For: Jun 30

Fri, 07 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260807/26891585.html

Form 10-Q IMPACT BIOMEDICAL INC. For: Mar 31

Tue, 12 May 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260512/26478831.html

Form 10-Q IMPACT BIOMEDICAL INC. For: Mar 31

Tue, 12 May 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260512/26478831.html

Form 144 IMPACT BIOMEDICAL INC. Filed by: DSS, INC.

Wed, 29 Apr 2026 18:09:00 -0400
si-local-file:///var/storage/secattach/20260429/26397354.html

Form 144 IMPACT BIOMEDICAL INC. Filed by: DSS, INC.

Wed, 29 Apr 2026 18:09:00 -0400
si-local-file:///var/storage/secattach/20260429/26397354.html

Form S-8 POS IMPACT BIOMEDICAL INC.

Wed, 22 Apr 2026 16:46:00 -0400
si-local-file:///var/storage/secattach/20260422/26352217.html